Life Sciences Archive » December, 2010

Life Sciences - December, 2010

141 articles

• Defense Bar Is Big Winner In 2010 Securities Rulings
• Bilski Headlines Influential IP Rulings In 2010
• Skilling Set Pace For White Collar Rulings In 2010
• Whistleblowers Key To Big Pharma PL Deals In 2010
• Down Economy Fueled Employment Settlements In 2010
• Competition Cases To Watch In 2011
• Health Care Regulation To Watch In 2011
• Copyright, Trademark Suits Netted Big Payouts In 2010
• Experts In Hot Seat In 2010 Product Liability Rulings
• Product Liability Cases To Watch In 2011
• Antitrust Defendants Score Windfall In 2010
• Technology Cases To Watch In 2011
• Fed. Circ. Nixes Deal In Sun Pharma Eloxatin Suit
• Genentech Fights FDA's Downgrade Of Avastin
• SEC Sues InterMune Options Buyers Over Inside Tips
• 3M, Others Urge US To Back High Infringement Standard
• Pfizer Yanks More Lipitor After Odor Problems
• FDA Announces Recall Of Abbott Diabetic Test Strips
• RyMed To Fight Infringement Verdict Over IV Patents
• Ex-UBS Banker Pleads Guilty To Insider Trading Scheme
• Defeating Joinder In Medical Device And Drug Cases
• Sales Reps Hit Daiichi Sankyo With FLSA Action
• Obama Inks $250B Short-Term Funding Bill
• Cleary Gottlieb Reps DSM In $1B Martek Acquisition
• Whistleblower Groups Say SEC Reward Plan Falls Short
• Senate Sends Short-Term Spending Bill To House
• Wyeth Beats W.Va. Fraud Suit Over Hormone Drugs
• Wyeth Loses Bid To Take Novartis IP Suit To Calif.
• Dey To Pay $280M To End Drug Price Inflation Suit
• Bill Seeks Overhaul Of Global Drug Safety Rules
• Cobalt Defense Nixed In Suit Over Generic Boniva
• Czech Energy Cos. Blocked Antitrust Raid, EU Says
• Oracle Drug Software Infringes Patent, Suit Says
• Issa Seeks FDA Probe Into Maker Of Recalled Rolaids
• Bilski Doesn't Doom Prometheus Patents: Fed. Circ.
• Ex-CV Sales Rep Drops Ranexa Marketing Suit
• Pharma Co. Says Insurer Owes It For Reactor Shutdown
• FDA Finds Quality Breaches At J&J Drug Plant
• Mylan Faces Suit Over Orapred ANDA
• Contraceptive Makers Denied Quick End To Patent Suit
• Novo, Sandoz Reach Deal Over Generic Prandin
• Senate Scraps $1.1T Spending Bill
• Bioethics Panel OKs Synthetic Bio, Urges Oversight
• Siemens Partially Off Hook In Lab Test Patent Suit
• PepperBall, Exec Beat $4.8M Securities Fraud Suit
• Medicis Hits Nycomed Unit With 3rd Vanos Patent Suit
• Fen-Phen Atty Deserved Policy Rescission: Insurer
• FTC Urges 11th Circ. To Revive Pay-For-Delay Case
• US Criticizes Planned Parenthood In Overbilling Case
• Generics Cos. Prevail In AstraZeneca's Crestor Suit
• Italy Fines 15 Cos. €81M In Body Care Antitrust Probe
• Case Study: FTC V. Ovation
• Feds Defend 10-Year Sentence For InterMune Exec
• Elan, Eisai To Pay $214M Over Zonegran Marketing
• Respirator Makers Dodge Worker's Asbestos Claims
• FDA Moves To Pull Breast Cancer Approval For Avastin
• Pfizer Wins OK For $75M Deal In Shareholder Suits
• Stryker Sues Zimmer Over Wound System Patent
• FDA Warns Of Hidden Ingredients In Supplements
• In-House Lawyers Attack SEC Whistleblower Program
• A Review Of 2010 Antitrust Class Actions
• Feds Reverse Course, Intervene In Guidant FCA Suit
• Teva's $70M ARS Suit V. Deutsche Tossed For Good
• Covidien Unit Targets Watson Over Generic Exalgo
• Senate Unveils $1.1T Omnibus Spending Bill
• Illumina Suit Over Gene Tech Patents Gets The Boot
• Novartis Finishes Up $51.6B Alcon Purchase
• 3rd Circ. Won't Revive Cephalon Shareholder Case
• FDA Warns Airgas Over Poor Records, Contamination
• J&J Hit With $50M Verdict In Pa. Medicare Suit
• Teva Settles In Bayer Suit Over Generic Yaz
• Ex-Professor Can't Toss St. John's Drug Research Suit
• Matrixx To Pay $15.5M In Zicam MDL
• Purdue Execs Can't Shake Ban From Federal Funds
• Vitamin Maker To Pay FDA $2M Over Health Claims
• Mylan Asks High Court To Review Generics Rulings
• 8th Circ. Shuts Down Medtronic ERISA Action
• Lloyd's Sues To Block Pacific Energy Volcano Claim
• Have Yourself A Merry, Lawsuit-Free Holiday Party
• Galderma Offers $978M For Sweden's Q-Med
• High Court Won't Consider Medical Device Case
• AntiCancer Sues Cellsight Over Tumor Detection IP
• Supreme Court Seeks US Input On Definiteness
• Supreme Court To Rule On Generics Labeling Laws
• MMSEA And Product Liability Claims
• Blue Cross, Others Booted In Pfizer Neurontin MDL
• Japan Orders J&J To Nix Acuvue Price-Display Ban
• Molecular Insight Enters Ch. 11 With $45M Finance Plan
• 2 Accused In Sequenom, EXAS Insider Trading Case
• VNUS Wins $45M Jury Verdict In Medical Laser IP Suit
• Pfizer Used Corruption Info To Pressure Official: Cable
• Supreme Court Weighs Major Shift On Invalidity
• Humana Drops Walgreen Drug Plan Comparisons Suit
• Mental Health: Fair Game In Disability Cases?
• Pfizer Pulls Hypertension Drug Thelin From Market
• Feds Subpoena Medtronic Over Neurostimulator Sales
• J&J Unit Recalls 13M Packages Of Rolaids
• Jenner & Block Adds Ex-Kirkland IP Litigator In LA
• Issa To Head House Oversight Committee
• Whistleblower Suit Over Bone Growth Device Stays Put
• 4th Circ. Affirms UK Jurisdiction In Contract Spat
• J&J Hit With $1.8M Verdict In Levaquin MDL
• 6 Cases Move Forward In Novartis MDL Over Bone Drugs
• Implications Of Genzyme: Loss Under A D&O Policy
• Sales Rep Hits Merck With Overtime Class Action
• EU Fines French Pharmacists €5M For Price-Fixing
• Cravath Reps J&J In $2.3B Bid For Crucell
• Exactech To Pay $3M To Settle Kickbacks Case
• Richards Layton IT Guy Accused Of Insider Trading
• Abbott, Others To Pay $421M Over Drug Price Hikes
• Medicare Stent Scam Cost $3.8M, Senate Report Says
• Cipro Buyers Urge High Court To Rule On Pay-For-Delay
• 9th Circ. Nixes En Banc Bid In Humana Marketing Suit
• Philips' Suit Over Defibrillator Patent Stays Alive
• Reckitt, Watson Drop Patent In Suit Over Mucinex ANDA
• Pfizer Proposes $75M Fund To Settle Shareholder Suits
• Pfizer Wins Verdict In Suit Over Prempro-Cancer Link
• Novatel Marks MiFi Wares With Expired Patents: Suit
• Pharmacy Drops Provigil Class Suit Against Cephalon
• Humana Sues Walgreen Over Drug Cost Comparisons
• Shire Sues Impax, Watson Over Generic Intuniv
• McNeil Asks High Court To Review Drug Failure To Warn
• Judge Tosses Part Of Ex-Wyeth Exec's Firing Suit
• What To Do When Seed Money Gets Personal
• The Best Part Of Waking Up
• EU Antitrust Raids Target AstraZeneca
• Allergan False Marking Case Survives Dismissal Bid
• AstraZeneca Seeks To Halt Mylan's 2nd Seroquel ANDA
• Stryker Loses Bid To Toss Pain Pump Suits
• Momenta, Sandoz Sue Teva Over Lovenox Generic
• Equity Re-Emerges As Strategic M&A Currency: Report
• J&J Recalls Mylanta To Revise Alcohol Labeling
• The Importance Of I4i V. Microsoft
• Univ. Of Wash. Targets GE Over Ultrasound Patent
• Ex-GSK Atty Pleads Not Guilty To FDA Probe Charges
• EU, India Near Settlement In Drug Seizure Row
• 3M, Funai, Others Hit With False Marking Suits
• Novo Patent Fight Over Prandin To Stay In Minn.
• Plaintiffs Exit Bayer MDL But Still Face Discovery
• Ropes & Gray Reps Axcan In $583M Eurand Deal
• The SEC's Lessons For Medical Consultants